Assessment of alpha-galactosylceramide as a novel adjuvant for pandemic influenza: A virua vaccine

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/400584

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The occurrence of human infections with pathogenic avian H5N1 Influenza A viruses was the first documentation of these viruses demonstrating an ability to directly transmit from birds to humans. The virulent nature of these infections, and the fact that there is no pre-existing immunity to these viruses in the human population has raised the concern that these viruses may emerge to cause the next influenza pandemic. Vaccination is our most effective way of protecting against influenza infection, however there are no commercially available avian influenza vaccines available. Moreover, recent evidence suggests current vaccines strategies may be less than effective. This proposal aims to evaluate the efficacy of a novel vaccine strategy that promotes immune protection against a potential pandemic influenza strain.

Funded Activity Details

Start Date: 01-01-2006

End Date: 01-01-2007

Funding Scheme: NHMRC Strategic Awards

Funding Amount: $220,042.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Immunology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Immune response | Influenza | Vaccine development | Vaccine efficcacy | Viral immunity

Related Links